FORA Capital LLC Cuts Holdings in Johnson & Johnson $JNJ

Key Points

• FORA Capital LLC has reduced its stake in Johnson & Johnson by 39.1%, holding now 12,983 shares valued at approximately $2,153,000.
• Analysts have varied opinions on JNJ stock, with a consensus target price of $176.29 and ratings ranging from Strong Buy to Hold.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, resulting in an annualized dividend of $5.20 and a yield of 2.9%.

FORA Capital LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 39.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,983 shares of the company's stock after selling 8,343 shares during the period. FORA Capital LLC's holdings in Johnson & Johnson were worth $2,153,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. Hudson Value Partners LLC raised its stake in shares of Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares in the last quarter. Bellwether Advisors LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $97,000. Perbak Capital Partners LLP purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $1,554,000. Finally, AQR Capital Management LLC raised its stake in shares of Johnson & Johnson by 9.9% during the 4th quarter. AQR Capital Management LLC now owns 3,472,635 shares of the company's stock worth $500,094,000 after buying an additional 313,672 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $1.29 during trading hours on Thursday, reaching $175.50. 6,423,524 shares of the company traded hands, compared to its average volume of 8,630,407. The firm's 50-day moving average is $165.45 and its 200-day moving average is $159.86. The stock has a market cap of $422.67 billion, a P/E ratio of 18.77, a P/E/G ratio of 2.25 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on JNJ. Royal Bank Of Canada increased their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Bank of America upped their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. UBS Group upped their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Finally, Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.